Hawaii 2024 Regular Session

Hawaii Senate Bill SB1454 Compare Versions

Only one version of the bill is available at this time.

Old	New	Differences
1	1	THE SENATE S.B. NO. 1454 THIRTY-SECOND LEGISLATURE, 2023 S.D. 2 STATE OF HAWAII A BILL FOR AN ACT RELATING TO PSILOCYBIN. BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF HAWAII:
2	2
3	3	THE SENATE S.B. NO. 1454
4	4	THIRTY-SECOND LEGISLATURE, 2023 S.D. 2
5	5	STATE OF HAWAII
6	6
7	7	THE SENATE
8	8
9	9	S.B. NO.
10	10
11	11	1454
12	12
13	13	THIRTY-SECOND LEGISLATURE, 2023
14	14
15	15	S.D. 2
16	16
17	17	STATE OF HAWAII
18	18
19	19
20	20
21	21
22	22
23	23
24	24
25	25
26	26
27	27
28	28
29	29
30	30
31	31	A BILL FOR AN ACT
32	32
33	33
34	34
35	35
36	36
37	37	RELATING TO PSILOCYBIN.
38	38
39	39
40	40
41	41
42	42
43	43	BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF HAWAII:
44	44
45	45
46	46
47	47	SECTION 1. The legislature finds that there is heightened awareness of the detrimental effects of untreated and maltreated mental health in the State's population. With a shortage of mental health professionals and appropriate mental health care, the State must actively consider innovative and effective treatment options to address this pressing need. The legislature further finds that psilocybin has been found to be very effective in treating a variety of mental health conditions, including post-traumatic stress disorder, depression, anxiety, and end-of-life psychological distress. As a result, the United States Food and Drug Administration has designated treatment that uses psilocybin in a therapeutic manner for treatment-resistant depression as a "breakthrough therapy". The legislature also finds that at least two states, Oregon and Colorado, have found that legalizing medicinal psilocybin is a valuable tool in dealing with various mental health conditions. Accordingly, the purpose of this Act is to establish the therapeutic psilocybin working group, which shall: (1) Examine the medicinal and therapeutic effects of psilocybin or psilocybin-based products on mental health, including post-traumatic stress disorder, depression, anxiety, and end-of-life psychological distress; (2) Examine the effectiveness of medicinal and therapeutic uses of psilocybin or psilocybin-based products in treating mental health in the two states that have legalized medicinal psilocybin, Oregon and Colorado; and (3) Determine and develop a long-term strategic plan to ensure the safe availability and accessibility of affordable therapeutic psilocybin or psilocybin-based products for adults twenty-one years of age or older. SECTION 2. (a) There is established a therapeutic psilocybin working group within the department of health for administrative purposes. (b) The working group shall: (1) Examine federal, state, and local laws, regulations, administrative rules, and procedures regarding the therapeutic use of psilocybin; (2) Examine medical, psychological, and scientific studies, research, and other information relating to the efficacy and safety of psilocybin or psilocybin‑based products in treating mental health disorders, including post-traumatic stress disorder, depression, anxiety, and end-of-life psychological distress; (3) Examine existing laws, requirements, and guidelines in jurisdictions in which psilocybin or psilocybin-based products are legally used to treat mental health conditions; and (4) If appropriate, determine and develop a long-term strategic plan to ensure the safe availability and accessibility of affordable therapeutic psilocybin or psilocybin-based products for adults twenty-one years of age or older. (c) The working group shall consist of the following individuals: (1) The executive director of the office of wellness and resilience, or the executive director's respective designee, who shall serve as chairperson of the working group; (2) The attorney general, or the attorney general's respective designee; (3) The dean of the John A. Burns school of medicine at the University of Hawaii at Manoa, or the dean's respective designee; (4) The chairpersons of the senate and house of representatives standing committees whose purview include health and the judiciary, or their respective designees; (5) The chairperson of the Hawaii state council on mental health, or the chairperson's respective designee; (6) A physician duly licensed pursuant to chapter 453, Hawaii Revised Statutes, or an advanced practice registered nurse who is authorized to prescribe psychotropic medication and is duly licensed pursuant to chapter 457, Hawaii Revised Statutes, as invited by the chairperson of the working group; (7) A psychiatrist duly licensed pursuant to chapter 453, Hawaii Revised Statutes, as invited by the chairperson of the working group; and (8) Other interested parties with relevant experience and expertise, as invited by the chairperson of the working group. (d) The members of the working group shall serve without compensation but shall be reimbursed for expenses, including travel expenses, necessary for the performance of their duties. No member of the working group shall be subject to chapter 84, Hawaii Revised Statutes, solely because of the member's participation in the working group. (e) The working group shall submit a report of its findings and recommendations, including any proposed legislation, to the legislature no later than twenty days prior to the convening of the regular session of 2025. (f) The working group shall be dissolved on June 30, 2025. SECTION 3. There is appropriated out of the general revenues of the State of Hawaii the sum of $ or so much thereof as may be necessary for fiscal year 2023-2024 and the same sum or so much thereof as may be necessary for fiscal year 2024-2025 for the therapeutic psilocybin working group. The sums appropriated shall be expended by the department of health for the purposes of this Act. SECTION 4. This Act shall take effect on December 31, 2050.
48	48
49	49	SECTION 1. The legislature finds that there is heightened awareness of the detrimental effects of untreated and maltreated mental health in the State's population. With a shortage of mental health professionals and appropriate mental health care, the State must actively consider innovative and effective treatment options to address this pressing need.
50	50
51	51	The legislature further finds that psilocybin has been found to be very effective in treating a variety of mental health conditions, including post-traumatic stress disorder, depression, anxiety, and end-of-life psychological distress. As a result, the United States Food and Drug Administration has designated treatment that uses psilocybin in a therapeutic manner for treatment-resistant depression as a "breakthrough therapy".
52	52
53	53	The legislature also finds that at least two states, Oregon and Colorado, have found that legalizing medicinal psilocybin is a valuable tool in dealing with various mental health conditions.
54	54
55	55	Accordingly, the purpose of this Act is to establish the therapeutic psilocybin working group, which shall:
56	56
57	57	(1) Examine the medicinal and therapeutic effects of psilocybin or psilocybin-based products on mental health, including post-traumatic stress disorder, depression, anxiety, and end-of-life psychological distress;
58	58
59	59	(2) Examine the effectiveness of medicinal and therapeutic uses of psilocybin or psilocybin-based products in treating mental health in the two states that have legalized medicinal psilocybin, Oregon and Colorado; and
60	60
61	61	(3) Determine and develop a long-term strategic plan to ensure the safe availability and accessibility of affordable therapeutic psilocybin or psilocybin-based products for adults twenty-one years of age or older.
62	62
63	63	SECTION 2. (a) There is established a therapeutic psilocybin working group within the department of health for administrative purposes.
64	64
65	65	(b) The working group shall:
66	66
67	67	(1) Examine federal, state, and local laws, regulations, administrative rules, and procedures regarding the therapeutic use of psilocybin;
68	68
69	69	(2) Examine medical, psychological, and scientific studies, research, and other information relating to the efficacy and safety of psilocybin or psilocybin‑based products in treating mental health disorders, including post-traumatic stress disorder, depression, anxiety, and end-of-life psychological distress;
70	70
71	71	(3) Examine existing laws, requirements, and guidelines in jurisdictions in which psilocybin or psilocybin-based products are legally used to treat mental health conditions; and
72	72
73	73	(4) If appropriate, determine and develop a long-term strategic plan to ensure the safe availability and accessibility of affordable therapeutic psilocybin or psilocybin-based products for adults twenty-one years of age or older.
74	74
75	75	(c) The working group shall consist of the following individuals:
76	76
77	77	(1) The executive director of the office of wellness and resilience, or the executive director's respective designee, who shall serve as chairperson of the working group;
78	78
79	79	(2) The attorney general, or the attorney general's respective designee;
80	80
81	81	(3) The dean of the John A. Burns school of medicine at the University of Hawaii at Manoa, or the dean's respective designee;
82	82
83	83	(4) The chairpersons of the senate and house of representatives standing committees whose purview include health and the judiciary, or their respective designees;
84	84
85	85	(5) The chairperson of the Hawaii state council on mental health, or the chairperson's respective designee;
86	86
87	87	(6) A physician duly licensed pursuant to chapter 453, Hawaii Revised Statutes, or an advanced practice registered nurse who is authorized to prescribe psychotropic medication and is duly licensed pursuant to chapter 457, Hawaii Revised Statutes, as invited by the chairperson of the working group;
88	88
89	89	(7) A psychiatrist duly licensed pursuant to chapter 453, Hawaii Revised Statutes, as invited by the chairperson of the working group; and
90	90
91	91	(8) Other interested parties with relevant experience and expertise, as invited by the chairperson of the working group.
92	92
93	93	(d) The members of the working group shall serve without compensation but shall be reimbursed for expenses, including travel expenses, necessary for the performance of their duties. No member of the working group shall be subject to chapter 84, Hawaii Revised Statutes, solely because of the member's participation in the working group.
94	94
95	95	(e) The working group shall submit a report of its findings and recommendations, including any proposed legislation, to the legislature no later than twenty days prior to the convening of the regular session of 2025.
96	96
97	97	(f) The working group shall be dissolved on June 30, 2025.
98	98
99	99	SECTION 3. There is appropriated out of the general revenues of the State of Hawaii the sum of $ or so much thereof as may be necessary for fiscal year 2023-2024 and the same sum or so much thereof as may be necessary for fiscal year 2024-2025 for the therapeutic psilocybin working group.
100	100
101	101	The sums appropriated shall be expended by the department of health for the purposes of this Act.
102	102
103	103	SECTION 4. This Act shall take effect on December 31, 2050.
104	104
105	105	Report Title: Psilocybin; DOH; Therapeutic Psilocybin Working Group; Report; Appropriation Description: Establishes the Therapeutic Psilocybin Working Group within the Department of Health. Requires the working group to examine the medicinal and therapeutic effects of psilocybin or psilocybin‑based products on mental health, report to the Legislature before the Regular Session of 2025, and dissolve on 6/30/2025. Appropriates funds. Effective 12/31/2050. (SD2) The summary description of legislation appearing on this page is for informational purposes only and is not legislation or evidence of legislative intent.
106	106
107	107
108	108
109	109
110	110
111	111	Report Title:
112	112
113	113	Psilocybin; DOH; Therapeutic Psilocybin Working Group; Report; Appropriation
114	114
115	115
116	116
117	117	Description:
118	118
119	119	Establishes the Therapeutic Psilocybin Working Group within the Department of Health. Requires the working group to examine the medicinal and therapeutic effects of psilocybin or psilocybin‑based products on mental health, report to the Legislature before the Regular Session of 2025, and dissolve on 6/30/2025. Appropriates funds. Effective 12/31/2050. (SD2)
120	120
121	121
122	122
123	123
124	124
125	125
126	126
127	127	The summary description of legislation appearing on this page is for informational purposes only and is not legislation or evidence of legislative intent.